Hetvi Bhatt

Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.

JOURNAL REVIEWED: Orbit

Latest Contribution

Orbit journal cover

Tocilizumab in Graves’ orbitopathy

2 February 2024 | | Oculoplastics, Orbit | Graves’ orbitopathy, Tocilizumab, corticosteroid

This prospective European study looks at the response to tocilizumab in corticosteroid-resistant disease. Tocilizumab (TCZ) is a monoclonal antibody that competitively inhibits IL-6 binding to its receptor. Unlike teprotumumab, the advantage of TCZ is that it is already used within...

Orbit journal cover

Ophthalmic presentations and outcomes in Erdheim-Chester disease

4 December 2023 | | Oculoplastics, Orbit | Erdheim–Chester disease, orbital Erdheim–Chester disease, vemurafenib

This is a comprehensive article describing clinical manifestations and pathogenesis of Erdheim-Chester disease (ECD) followed by a literature review of the available treatments. The authors look to compare historical treatment (HT) with vemurafenib, a BRAF inhibitor. ECD is a non-Langerhans...

Orbit journal cover

Differentiating orbital cellulitis from non-specific orbital inflammation

4 December 2023 | | Oculoplastics, Orbit | C-Reactive protein, Non-specific orbital inflammation, inflammatory markers, orbital cellulitis, white-cell count

This is a retrospective study looking at whether common laboratory investigations can help differentiate between orbital cellulitis (OC) and non-specific orbital inflammation (NSOI). NSOI is a diagnosis of exclusion following negative investigations for systemic diseases such as IgG4-related disease, granulomatosis...